
Tango Therapeutics (TNGX) Stock Forecast & Price Target
Tango Therapeutics (TNGX) Analyst Ratings
Bulls say
Tango Therapeutics is a promising biotechnology company with a focus on precision oncology therapies for the treatment of cancer, particularly in the areas of non-CNS and CNS cancers. The company's two lead MTAP-cooperative PRMT5 inhibitors hold potential in combination with RAS inhibitors for PDAC, although management's pivot away from monotherapy is a cause for caution. Additionally, while the 1L combo strategy is a more appealing option, the company's current $3.6B market cap already reflects a promising early signal and the limited follow-up data expected in 2025 may not be enough to justify further investment at this time. Therefore, the company's stock is currently rated as Neutral with a price target of $24, reflecting potential risks of clinical and regulatory failure and potential challenges in achieving sales estimates.
Bears say
Tango Therapeutics is a biotechnology company with a focus on precision medicine for cancer treatment. While the company has promising pipeline products targeting PRMT5 and CoREST, its financials are concerning with a net loss of $45.5M in the first quarter of 2026 and only enough cash to fund operations until 2028. Additionally, the company's plans for future clinical trials and partnerships may delay the potential for meaningful revenue in the near future, leading to a negative outlook on the stock.
This aggregate rating is based on analysts' research of Tango Therapeutics and is not a guaranteed prediction by Public.com or investment advice.
Tango Therapeutics (TNGX) Analyst Forecast & Price Prediction
Start investing in Tango Therapeutics (TNGX)
Order type
Buy in
Order amount
Est. shares
0 shares